Bayer Reports Higher Sales During FY2025

USAgNet - 03/06/2026

The Bayer Group achieved its full-year targets for 2025 after having upgraded its currency-adjusted Group outlook for sales and earnings at the end of July. "We delivered that guidance, landing comfortably within the improved corridor," CEO Bill Anderson said at the company's Financial News Conference on Wednesday.

Commenting on the divisions, he explained that "Crop Science progressed in the first year of its profitability improvement program. A rejuvenated picture of our Pharmaceuticals business emerged, with launch medicines establishing themselves as growth drivers and others advancing through our pipeline to market. Our Consumer Health business suffered from market softness in the United States and China, but maintained the bottom line."

Looking ahead, Bayer expects 2026 to be a year of solid sales and stable earnings on a currency-adjusted basis. "That outlook is emblematic of the company's current strategic position: strong signs of progress, but still working on a comprehensive turnaround. We've made major gains across the company, but that work is not yet complete," Anderson explained, adding: "We have a clear picture of what needs to be done in every area."

Moreover, Bayer's multi-pronged strategy to contain the U.S. litigations proceeds apace, he noted, with the company having last month announced a class settlement agreement to resolve current and future claims relating to Roundup™ (glyphosate). In addition, Bayer continues to implement Dynamic Shared Ownership and expects to realize the targeted two billion euros in savings through the new operating model.

Group sales rose by 1.1 percent on a currency- and portfolio-adjusted basis (Fx & portfolio adj.) to 45.575 billion euros in 2025. There was a negative currency effect of 1.742 billion euros. EBITDA before special items decreased by 4.5 percent to 9.669 billion euros, and included a negative currency effect of 491 million euros that impacted all divisions. EBIT amounted to minus 1.077 billion euros (2024: minus 71 million euros) after net special charges of 6.185 billion euros (2024: 5.507 billion euros) that mainly resulted from litigation-related expenses.

Net income came in at minus 3.620 billion euros (2024: minus 2.552 billion euros). Core earnings per share decreased by 2.8 percent to 4.91 euros, mainly due to the decline in earnings in the Pharmaceuticals and Crop Science divisions. However, the improved financial result had a positive impact.

Free cash flow declined by 32.9 percent to 2.084 billion euros. Net financial debt as of December 31, 2025, came in at 29.843 billion euros, representing a reduction of 8.5 percent against year-end 2024 that was mainly driven by cash inflows from operating activities as well as positive currency effects of 1.370 billion euros. At the upcoming Annual Stockholders' Meeting on April 24, 2026, the company will be proposing a dividend of 0.11 euros per share for 2025, in line with the dividend paid for 2024.

« Return to Home Page